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disease. Baseline TGF-1, diabetes mellitus and serum albuminLow TGF-1 serum levels are a risk factor for atherosclerosis
levels proved to be the only independent contributors to ath-disease in ESRD patients.
erosclerotic risk in dialysis patients.Background. It is thought that transforming growth factor-1
(TGF-1) might be a key inhibitor of atherogenesis in non-
uremic patients. We evaluated the intra- and post-dialytic se-
rum levels of TGF-1 in uremic patients to assess if TGF-1 The incidence of cardiovascular disease, mainly related
is an independent risk factor for cardiovascular diseases, and to atherosclerosis, increases significantly in dialysis pa-
if any correlation exists between TGF-1 and any yet known tients, for whom it is the main cause of death [1]. Theatherosclerotic risk factors.
relative risk of mortality from ischemic heart disease hasMethods. We studied 155 patients who were on regular he-
been estimated as 22 times higher in dialysis patientsmodialysis, with or without clinically significant atherosclerotic
vascular disease. Forty-one apparently healthy people were than in the normal population, a risk similar to that of
enrolled as a control group. TGF-1 was evaluated during the survivors from a first myocardial infarction. The high
midweek dialysis session, at times 0, 30, and 120 minues, at incidence of vascular complications in dialysis patients
the end of the session, and 3 hours after the session’s end. All
also involves peripheral vascular disease and stroke, thehitherto known atherosclerotic risk factors also were evaluated.
high incidence of which likewise is thought to be relatedThe investigation was performed over a 24-month follow-up.
to an acceleration of atherogenesis. It is still controversialResults. TGF-1 values (mean  SD) in dialysis patients
were 26.64  7.0 ng/mL (N  155) compared with 42.31  whether uremic patients per se are prone to accelerated
6.0 ng/mL in the control group (N  41, P  0.0001). A weak atherogenesis, or whether the high cardiovascular mor-
inverse correlation emerged between TGF-1 and age (r  bidity and mortality are a consequence of various risk
0.28), TGF-1 and lipoprotein(a) [Lp(a); r0.35], TGF-1
factors already present in these patients right from theand C-reactive protein (CRP; r  0.27), and TGF-1 and
predialysis phase [2, 3].plasminogen activator inhibitor-1 (PAI-1; r  0.41). TGF-1
In hemodialysis patients, besides the well-known riskalso correlated with albumin (r  0.31). In the coronary heart
disease (CHD) group (N  32) the TGF-1 was 26.2  factors that can trigger the atherosclerotic process such
4.9 ng/mL; in the cerebrovascular disease (CVD) group (N  as old age, smoking, hypertension, hypercholesterolemia,
8) it was 26.7 3.7 ng/mL and in the peripheral vascular disease other factors such as hyperhomocysteinemia, hyperpara-
(PVD) group (N  9) it was 25.4  1.7 ng/mL. In dialysis thyroidism, malnutrition, and inflammation seem to ac-patients with no cardiovascular disease (N  80) TGF-1 was
celerate the process [4–6]. However, no combination of35.1  6.8 ng/mL (P  0.0001 vs. CHD, CVD and PVD pa-
the known risk factors has provided a convincing expla-tients). TGF-1 was significantly lower among those patients
with triple coronary vessel disease than with the other CHD nation of why accelerated atherosclerosis occurs in dial-
patients. The Cox analysis demonstrated that a 1 ng/mL reduc- ysis patients [7, 8]. Probably other mechanisms besides
tion in TGF-1 concentration was associated with a 9% in- these are triggered or accelerated by dialysis therapy or
crease in the relative risk of a cardiovascular event. by persisting uremia, and play an important role.
Conclusions. TGF-1 was significantly reduced in hemodial-
Atherosclerosis is a slowly progressing, inflammatory,ysis patients, in particular in those with severe cardiovascular
proliferative disease in which various cells such as macro-
phages, endothelial and smooth muscle cells (SMC) are in-
Key words: atherosclerosis, cardiovascular diseases, uremia, hemodialy- volved [9]. In the last few years, experimental evidence has
sis, ischemic heart disease, vascular complication. suggested that transforming growth factor-1 (TGF-1)
may have a key role in atherogenesis by inhibiting bothReceived for publication January 17, 2001
migration and proliferation of smooth muscle cells andand in revised form August 28, 2001
Accepted for publication August 30, 2001 macrophages and by protecting endothelial function
[10–12]. 2002 by the International Society of Nephrology
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Table 1. Baseline characteristics of the study populationPrevious studies in non-renal patients have demon-
strated the importance of cytokines or growth factors No. of patients 155
Sexin the atherosclerotic process and shown that athero-
Male 88sclerosis may be the result of an imbalance between Female 67
atherogenic and proliferative growth factors such as plate- Age years 62.314.2
Etiology of renal diseaselet-derived growth factor (PDGF), macrophage colony-
Chronic glomerulonephritis 30.1%stimulating factor (MCSF) and antiatherogenic and anti- Vascular 45.4%
inflammatory growth factors like TGF-1 [11–14]. Diabetes 5.4%
Chronic pyelonephritis 15.7%In the pathological changes that characterize the ath-
Adult polycystic kidney disease 2.4%erosclerotic process and plaque formation, the corner- Miscellaneous 1.0%
stone event is endothelial injury and the release of ath- Duration of hemodialysis months 74.381.2
Diabetes 5%erogenic growth factors [9]. Whatever the agent acting at
Hypertension 56.6%the site of injury, smooth muscle cells and macrophages HDL-C mg/dL 266
subsequently proliferate and migrate from the media. LDL-C mg/dLa 12530
Triglycerides mg/dL 189115This proliferation is the main event in the development
Smoking 10%of atherosclerosis. Lp(a) mg/dL 22.720.9
Transforming growth factor-1 is a 25 kD homodi- Homocysteine mmol/L 55.444.7
Albumin g/L 3.50.3meric pleiotropic growth factor secreted by many kinds of
C reactive protein mg/dL 1.82.6cell including macrophages, lymphocytes, smooth muscle Fibrinogen mg/dL 368126
cells and platelets. It is secreted in a latent inactive form
a Calculated by means of the Friedewald formula [55]
that is activated proteolytically by plasmin [15]. In turn,
plasmin is produced from plasminogen by tissue plasmin-
ogen activator, the production of which is blocked by
own hemodialysis treatment throughout the study. Allcompetitive inhibition from lipoprotein(a) [Lp(a)] and
patients were regularly treated three times weekly withplasminogen activator inhibitor 1 (PAI-1). These mole-
standard bicarbonate dialysis (62%) or hemodiafiltrationcules are therefore able to promote smooth muscle cell
(38%). The dialyzers used were hemophan (58%), poly-proliferation by relieving the inhibition caused by active
acrylonitrile (PAN; 12%), and polysulfone (30%). InTGF- [16, 17]. Two kinds of TGF- receptor (types I
all procedures the same heparinization modalities wereand II) have been identified on target cell membranes,
employed: in the washing phase, 2 liters of saline solutionboth receptors being required for TGF-1 signaling to
were used containing 20,000 IU of standard heparin inoccur [18].
single pass (Sodic Heparin; Vister by Parke-Davis, Ponty-The aims of our present study were to evaluate both
pool, UK), followed by 2000  500 IU in a continuousthe basal and the intradialytic serum levels of TGF-1
intradialytic infusion.in uremic patients and to assess whether TGF-1 is an
The distribution of TGF-1 values in the populationindependent risk factor for cardiovascular disease in the
per hemodialysis duration quartile is shown in Figure 1.hemodialysis population studied, checking for any rela-
Because there is a known genetic predisposition to betionship with cardiovascular disease in regular dialysis
high, intermediate or low TGF-1 producers in both thetreatment (RDT) patients. We also assessed for a corre-
dialysis population and the control group [20], we an-lation between TGF-1, the acute phase reactants, and
alyzed two single-nucleotide polymorphisms in the DNAany known atherosclerotic risk factors.
sequence encoding the leader sequence of the TGF-1
protein, located at position 869 (codon 10, T→C, leu-
METHODS cine→proline) and position915 (codon 25, G→C, argi-
The study began with a consecutive series of 155 Cau- nine→proline). The signal peptide sequence, where the
casian patients on regular hemodialysis treatment in our studied polymorphisms are located, was cleaved from the
dialysis unit. Baseline characteristics of the 88 males and TGF-1 precursor at codon 29. The signal sequence al-
67 females are reported in Table 1. lowed the new synthesized protein to be exported across
Their ages ranged from 30 to 85 years (mean age the membranes of the endoplasmatic reticulum [21, 22].
62.3  14.2 years). Hemodialysis treatment had been Alteration of the signal sequence, changing one amino
initiated 74.3 81.2 months before the baseline TGF-1 acid for another, can affect export efficiency.
serum level evaluation. All patients were on regular dial- The putative high haplotypes are T/T G/G and T/C G/G;
ysis treatment three times a week; the mean Kt/V (calcu- intermediate are T/C G/C, C/C G/G and T/T G/C; low
lated according to Daurgirdas’ second logarithmic for- producers are C/C G/C, C/C C/C, T/T C/C and T/C C/C.
mula) was 1.3  0.3 [19]; the diuresis was 200 mL/day Seventy-five patients (49%) from among the 155 se-
lected patients of our dialysis centre had a history orfor all the patients. Patients were maintained on their
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Table 2. Correlation between TGF-1 value and other baseline risk
factors for atherosclerotic disease
Variable r P
Age 0.28 0.04
Duration of hemodialysis 0.20 0.05
LDL-C 0.03 0.72
Triglycerides 0.09 0.34
Lp(a) 0.35 0.05
Homocysteine 0.07 0.41
Albumin 0.31 0.33
PAI-1 0.41 0.05
C reactive protein 0.27 0.05
Fibrinogen 0.05 0.23
ograms (15 patients). Peripheral vascular surgery had
not been performed later than three months before the
study started.
Eighty dialysis patients on entry to our study showed
no signs or symptoms of atherosclerosis disease, in theFig. 1. Distribution of transforming growth factor-1 (TGF-1) values
per hemodialysis duration quartile. The mean TGF-1 values became sense that none of the selected criteria was found in
significantly higher for males ( ) than females ( ) in the fourth quartile. their clinical history. Nonetheless, all these patients were
examined by vascular Doppler echography to exclude
significant and still silent atherosclerotic involvement of
these arteries, or the presence of atherosclerotic plaques.evidence of one or more “atherosclerotic related” pro-
Abdominal aorta, carotid arteries and iliac-femoral ar-cesses on entry to our study (Table 2). Clinically signifi-
teries were the vascular districts observed.cant atherosclerotic vascular disease was defined as the
Platelet basal levels did not differ between the dialy-presence of coronary heart disease (CHD), cerebrovas-
sis patients with and without atherosclerotic diseasescular disease (CVD), or peripheral vascular disease (PVD)
(230,000  23,000/mmc vs. 227,000  27,000/mmc, P as described in what follows.
NS) nor between 14 patients with severe CHD and 18Coronary heart disease was diagnosed by at least one
patients with mild CHD (223,000  28,000/mm3 vs.of the following criteria: (1) previous admission for docu-
228,000  22,000/mmc, P  NS).mented myocardial infarction, not later than three months
Of the 155 patients selected, 88 (56.6%) suffered frombefore the study started (elevated creatine kinase level
hypertension for which they were on antihypertensiveand electrocardiogram changes); (2) a clinical history of
treatment. Only 15 patients (9.6%) were receiving angio-symptoms consistent with angina confirmed by a positive
tensin-converting enzyme (ACE) inhibitors, 6 with rami-exercise stress test result; or (3) significant positive re-
pril 5  0 mg/day, and 9 with enalapril 10  5.5 mg/day.sults on coronary angiograms (stenosis 50% for 1 of
Forty-one apparently healthy people, comparable inthe 3 major vessels) or on thallium scan (defining fixed
age (63  11 years) and sex distribution (21 males andor reversible perfusion defects). In these patients CHD
20 females), were enrolled as a control group for TGF-1was diagnosed on the basis of their previous clinical and
serum level. This latter group also underwent an electro-instrumental backgrounds: these patients had undergone
cardiogram (ECG) and vascular Doppler echography, withthallium scan (30 patients) or coronary angiograms (25
the same criteria, to exclude ischemic myocardial diseasepatients) at least once prior to entry in the study.
and atherosclerotic disease. In these patients no patho-Cerebrovascular disease was defined by at least one
logical signs were found by the tests. All of the Dopplerof the following criteria: (1) a previous stroke (acute-
echography tests were performed by the same radiologist.onset irreversible neurological deficit) not later than
Platelet basal levels did not differ between the controlthree months before the study started, documented by
group and the dialysis patients, with and without athero-cerebral CT or MRI or by a physician in the patient’s
sclerosis: (238,000  34,000/mmc vs. 230,000  23,000/medical records, or (2) evidence of stenosis 50% for
mmc, P  NS, and 238,000  34,000/mmc vs 227,000 carotid vessels at Doppler echography. Peripheral vascu-
28,000/mmc, P  NS, respectively).lar disease was defined by the presence of claudicatio
intermittens, previous peripheral vascular surgery (7 pa-
Laboratory methodstients), including amputation for ischemic limb (3 pa-
The TGF-1 serum level was evaluated immediatelytients), or the presence of atherosclerotic plaques at
Doppler echography or at abdominal-iliac-femoral angi- before and during the midweek session; blood samples
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Table 3. Intra- and post-dialytic behavior of TGF-1 serum levels:from the arterial line were collected to check TGF-1
No difference was found reflecting the membrane used, by ANOVA
at times 0 (dialysis session start), 30 minutes, 120 minutes,
Time F Pat the end of the session (immediately before the extra-
0 0.661 NScorporeal volume reinfusion) and three hours after the ses-
30 minutes 0.548 NSsion’s end. Activated partial thromboplastin time (aPTT)
180 minutes 0.753 NS
values were checked at times 0, 30 minues, 120 minutes, 240 minutes 1.215 NS
3 hours 0.134 NSat the end of the session, and three hours afterwards.
During the same dialysis session a fasting blood sample
was drawn to check low-density lipoprotein (LDL-C), tri-
glycerides (TG), lipoprotein(a) [Lp(a)], homocysteine,
albumin, C-reactive protein (CRP), fibrinogen, and plas- used in conjuction with the D-mix, and 5 U/L of the
minogen activator inhibitor type 1 (PAI-1) from all pa- recombinant Taq polymerase (Perkin-Elmer Amplitaq
tients. Sampling was only performed at the dialysis start DNA Polymerase). The final reaction volume was 10 L.
(time 0). LDL-C, TG, albumin, CRP, fibrinogen and ho- The amplification program was run on a Perkin-Elmer
mocysteine were evaluated by standard laboratory meth- 9700 thermalcycler: 1 cycle of 96	C for 130 seconds, 63	C
ods; Lp(a) was evaluated by an immunometric method for 60 seconds; 9 cycles of 96	C for 10 seconds, 63	C for
(Bouty Inc., Sesto S, Giovanni, Italy), PAI-1 was evalu- 60 seconds, 20 cycles of 96	C for 10 seconds, 59	C for 50
ated by a chromatogenic method (Dade Behring Inc. seconds, 72	C for 30 seconds. PCR products were visual-
Milan, Italy). We used a Genomic Prep Blood DNA ized on a 2.5% agarose gel stained with ethidium bro-
Isolation Kit (Pharmacia Biotech, Inc., Uppsala, Swe- mide.
den). The dosage of TGF-1 was made as follows: first The protocol was approved by an Ethics Committee
a serum separator tube was used to allow the sample to and informed consent was obtained from all the patients.
clot for one hour at room temperature. In order to obtain
Follow-up studiesa complete release of TGF-1, blood samples were main-
tained overnight at 2 to 8	C before centrifugation. Then The investigation was based on a prospective study en-
the samples were centrifuged at 1000
 g for 10 minutes, tailing 24 months of follow-up. The requirement for pa-
and the serum obtained was stored at 70	C. To convert tients to return to our dialysis unit three times a week
any inactive TGF-1 to an active form, the samples were facilitated the determination of clinical and laboratory
first acidified (by adding 100 L of a 2.5 N acetic acid/10 findings associated with baseline TGF-1 levels during
mol/L urea solution to 100L of serum) and then restored the follow up.
to pH 7.2 to 7.6 by 100 L of a 2.7 N NaOH/1 mol/L Date and cause of death were recorded directly for
HEPES solution. deaths occurring in our Unit and from interviews with the
Concentrations were determined by means of a solid physicians who verified the cause when death occurred
phase, TGF-1–specific sandwich enzyme-linked immu- outside the dialysis unit.
nosorbent assay (ELISA) (Quantykine; R&D Systems,
The cause of death was classified as a cardiovascular
Minneapolis, MN, USA). The minimum detectable level
event (myocardial infarction, sudden death, and stroke)of TGF-1 was 7 pg/mL.
or non-cardiovascular event (infection, neoplasms, mas-The genotype polymorphism was determined as fol-
sive gastrointestinal bleeding, others including uncertainlows: blood from all individuals was collected in sterile
causes when no clear atherosclerotic event was found).tubes containing 0.1% of ethylenediaminetetraacetic
acid (EDTA); genomic DNA was extracted using a Ge- Statistical analysis
nomic PrepBlood DNA Isolation Kit (Pharmacia Bio-
Statistical analysis was performed by the Statisticaltech. Inc.). DNA samples were screened for mutations
Package for the Social Sciences (SPSS for Windowsin the TGF-1 gene by polymerase chain reaction (PCR)
Software Package; version 9.0.1). Data are presented assingle strand polymosphism (SSP) methodology with the
means  standard deviation.Cytokine Genotyping Tray Kit (One Lambda Inc., Los
The Student t test was used for group comparison ofAngeles, CA, USA). Pre-optimized primers were pre-
continuous variables with normal population distribu-sented, dried in different wells of a 96-well 0.2-mL thin-
tion (Kolmogorov-Smirnov test, Z  0.77).walled tube tray for PCR and made ready for the addi-
The ANOVA test was performed to evaluate the intration of DNA samples, recombinant Taq polymerase, and
and post-dialytic behavior of serum TGF-1 (Table 3).specially formulated dNTP-buffer mix (D-Mix). Each
Linear regression analysis was performed to evaluatetray included a negative control reaction tube and an
the presence of a statistically significant relationship be-internal control PCR product, amplified from the hu-
tween two parameters, in this case between TGF-1 andman-globin gene. The amount of the primer was adjusted
for optimal amplification of 100 ng of sample DNA when the other baseline variables commonly known as risk
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producers, 25.2  11.0 ng/mL, and the 8 (5%) low pro-
ducers, 26.5 9.2 ng/mL (Table 4). In the control group,
the same percentage distribution of dialysis patients was
found: 33 (80%) patients were high producers, 6 (14%)
were intermediate and 2 (5%) low producers.
Because a certain number of our hemodialysis patients
had clinical evidence of atherosclerosis on entry to the
study, the TGF-1 levels were compared among the
three groups of CHD, CVD and PVD patients (Table 5).
In the CHD group (N  32), the TGF-1 level was
26.2  4.9 ng/mL, in the CVD group (N  8) 26.7 
3.7 ng/mL and in the PVD (N  9) 25.4  1.7 ng/mL
(P  NS). In hemodialysis patients with no evidence
of cardiovascular disease the TGF-1 mean value was
35.1  6.8 ng/mL (P  0.0001 vs. CHD, CVD and PVD
patients). Interestingly, in patients with simultaneous ev-
idence of CHD, CVD and PVD disease (N  20),
TGF-1 was significantly lower (mean 16.7 4.0 ng/mL;
P  0.0001 again versus those with CHD, CVD or PVD
alone). Furthermore, the TGF-1 serum concentration
was significantly lower (20  3 ng/mL) among those
patients of the CHD group with triple coronary vessel
disease (N 14) than among patients of the same group
with mild CHD (N  18), whose serum concentration
was 30.8  5 ng/mL, P  0.001 (Fig. 3).Fig. 2. Dot plot showing TGF-1 values in hemodialysis patients
(26.6  7 ng/mL) versus controls (42.3  6 ng/mL, P  0.0001). Transforming growth factor-1 serum levels were
again nearly the same in hypertensive patients (25.2 
8.4 ng/mL) versus non-hypertensives (28.4 9.3 ng/mL)
and in diabetics (25.4  8.7 ng/mL) versus non-diabetics
factors for atherosclerosis: age, sex, LDL-C, TG, Lp(a), (26.9  9.0 ng/mL), and they did not correlate with the
homocysteine, albumin, CRP, fibrinogen, and PAI-1. different causes of end-stage renal disease.
Multivariate analysis was performed using the Cox From the analysis of the association of TGF-1 base-
proportional hazard model to determine the indepen- line serum levels with other potential risk factors for
dent association of baseline parameters with the risk of atherosclerotic clinical events, no significant correlation
cardiovascular death during the follow-up period. Vari- was found between TGF-1 and LDL-C, TG, homocys-
ables entered in the final analysis were: age, diabetes, teine and fibrinogen (Table 2). A weak inverse correla-
systolic arterial pressure, dyastolic arterial pressure, tion emerged between TGF-1 and age (r  0.28),
LDL, TGF-1 and albumin. TGF-1 and Lp(a) (r  0.35), TGF-1 and CRP (r 
Kaplan-Meier event-free survival curves were ana- 0.27) and, finally, between TGF-1 and PAI-1 (r 
lyzed separately on the two groups with TGF-1 serum 0.41); TGF-1 also proved to correlate with albumin
level respectively above and below the mean value (r 0.31). In the population studied a positive moderate
26.64 ng/mL. correlation also was found between CRP and albumin
(r  0.63) and CRP and Lp(a) (r  0.52).
Transforming growth factor-1 serum levels wereRESULTS
evaluated before the start of the midweek dialysis ses-
Baseline findings sion, separating patients dialyzed with hemophan (24.8
The mean TGF-1 concentration in our hemodialysis 7.4 ng/mL) from those on PAN (mean value 26.5  5.4
patients was 26.6  7 ng/mL compared with 42.3  ng/mL) and those on polysulfonee (27.7  9.3 ng/mL).
6 ng/mL in the control group (P  0.0001; Fig. 2). No No statistically significant difference was found either
significant difference in TGF-1 was found between among the three groups of membranes or between the
males (25.2  10.5 ng/mL) and females (28.1  6.8 two techniques (standard bicarbonate dialysis 25.8 5.4
ng/mL) among the hemodialysis population. ng/mL vs. hemodiafiltration 26.9 4.7 ng/mL). Checking
Again in the dialysis group, no significant difference the intradialytic behavior of TGF-1 serum levels, only
in TGF-1 was found between the 129 (83%) high pro- at 30 minutes was there a significant reduction (by about
30%, P  0.001), without any difference reflecting theducers, 27.2  8.0 ng/mL, the 18 (11%) intermediate
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Table 4. Genotypes and TGF-1 levels in hemodialysis patients
Producer High Intermediate Low
Codon 10 T/C T/T C/C T/C C/C C/C
Codon 25 G/G G/G G/G G/C C/C G/C
TGF-1 ng/mL 26.58.2 27.99.5 19.810 30.511.5 28.48.7 24.59.5
Frequency % 28 55 6 5 3 2
Table 5. Transforming growth factor-1 values in patients with and
without atherosclerotic disease
Clinical event N patients TGF-1 ng/mL Significancea
Atherosclerotic disease 75 26.12.3 0.0001
CHD only 32 26.24.9 0.0001
CVD only 8 26.73.7 0.0001
PVD only 9 25.41.7 0.0001
CHDPVDCVD 26 16.74.0 0.0001
No atherosclerotic disease 80 35.16.8 —
a Student t test versus patients with no atherosclerotic disease.
Fig. 3. TGF-1 in the coronary heart disease (CHD) group showing
patients with mild CHD versus patients with triple coronary vessel disease.
Fig. 4. Intradialytic behavior of TGF-1 serum levels. No difference*P  0.001.
was found reflecting the membrane or technique used using the Student
t test. At 30 minutes a significant (P  0.001) reduction in TGF-1 was
observed over T0 values. Symbols are: () hemophan; () polysulfone;
() PAN.
membrane or the technique used (Fig. 4 and Table 3).
By three hours after the session’s end, levels had reverted
to basal values (Fig. 4).
Table 6. Cardiovascular events and causes of death in the study
Looking at the distribution of TGF-1 values per he- cohort during follow-up
modialysis duration quartile (Fig. 1), interestingly the
Cardiovascular eventsmean values were nearly the same until 113 months of (fatal and non-fatal) N Causes of death N
dialysis (PNS), becoming significantly higher, but only
Angina pectoris 41 Cardiovascular 17
for the male gender, in the fourth quartile (113 months; Heart failure 18 Myocardial infarction 7
Arrhythmia 10 Stroke 4P  0.05).
Peripheral artery disease 10 Heart failure 3
Transient ischemic attack 9 Sudden death 2Follow-up
Stroke 7 Arrhythmia 1
Sudden death 2 Non-cardiovascularDuring the 24 months of follow-up 18 deaths occurred
Pulmonary embolism 1 Neoplasia 1(17 cardiovascular and 1 non-cardiovascular; Table 6).
Three patients discontinued dialysis treatment after re-
nal transplantation.
risk of cardiovascular death. Baseline TGF-1, serumAge, LDL, systolic arterial pressure, diastolic arterial
albumin and the presence of diabetes mellitus levelspressure, male sex, diabetes, albumin and TGF-1 levels
proved the only independent contributors to risk in thewere entered into the stepwise logistic regression analy-
sis as variables to determine their contribution to the regression model (Table 7).
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Table 7. Multiple logistic regression analysis of risk factors for cardiovascular death
Variable  SEM Odds ratio 95% Confidence interval P
LDL-C 0.092 0.0115 0.99 (0.96, 1.01) 0.42
PAS 0.069 0.0317 0.99 (0.93, 1.05) 0.82
PAD 0.041 0.0506 1.04 (0.94, 1.15) 0.40
Diabetes 1.2194 0.615 3.38 (1.01, 11.3) 0.04
Albumin 0.785 0.0052 1.1 (0.93, 1.01) 0.02
Age at event 0.044 0.0037 1.0 (0.99, 1.00) 0.98
TGF-1 0.898 0.0451 0.91 (0.83, 0.99) 0.04
Fig. 6. Mortality histograms for quartiles of TGF-1 levels. The higher
the TGF-1 value, the lower the percentage of deaths. Each histogram
shows the percentage of deaths in the group with TGF-1 levels indi-
Fig. 5. Kaplan-Meier survival curves. Comparison between the TGF-1 cated. In the first quartile there were 9 deaths (28.6%), in the second
high values group (26.64 ng/mL; solid line) and the TGF-1 low values quartile 7 (18.5%), in the third there was 1 death (6.7%), in the fourth
group (26.64 ng/mL; dashed line) was P  0.001 by the log rank test. quartile with the highest TGF-1 levels no death occurred.
The Cox analysis demonstrated that a 1 ng/mL reduc- DISCUSSION
tion in TGF-1 concentration was associated with a 9% The importance of cardiovascular disease in RDT pa-
increase in the relative risk of undergoing a cardiovas- tients emerges from both clinical and statistical evalua-
cular event (P  0.04). The presence of diabetes (P  tions that show the precocity and the impact of athero-
0.04) and hypoalbuminemia (P  0.02) were the only sclerotic disease on dialysis patients in terms of morbidity
parameters that contributed to the regression model. and mortality.
Finally, using the mean TGF-1 concentration value No combination of Framingham risk factors has pro-
of 26.64 ng/mL as an arbitrary cut off value to define vided a convincing explanation of why dialysis patients
patients with higher and lower TGF-1 values, the Kap- have accelerated atherosclerosis.
lan-Meier survival curves were calculated separately. Recently several experimental studies in non-renal pa-
The Kaplan-Meier survival curves showed significant tients have focused on the role cytokines may play in gen-
differences between the two groups: P 0.001 by the log erating atherosclerosis. Artherosclerotic changes could
rank test (Fig. 5). be partly an expression of an imbalance between anti-
To confirm the Kaplan-Meier survival curves, mortal- atherogenic (TGF-1) and atherogenic (MCSF and IL-6)
ity histograms for quartiles of TGF-1 levels were pro- cytokines and growth factors [11–14].
vided (Fig. 6). Cut-off values for quartiles were TGF-1 Transforming growth factor-1 is a pleiotropic pro-
concentrations of 19.7 ng/mL, 26.7 ng/mL and 32.8 ng/mL. tein. Some of its effects are the result of its neutralizing
The data demonstrated that the higher the TGF-1 value, the main inflammatory cytokines by inhibiting their syn-
the lower the percentage of deaths: in the first quartile thesis [as with tumor necrosis factor-alpha (TNF-)] or
there were 9 deaths (28.6%), in the second quartile 7 by downscaling their effects (as with IL-1, interferon-
(18.5%), in the third there was one death (6.7%), and and TNF-) [23, 24].
in the fourth quartile with the highest TGF-1 levels no Evidence also exists that TGF-1 down-regulates (1) the
inflammatory cytokine-induced expression of VCAM-1,death occurred.
Stefoni et al: Low TGF-b1 levels and atherosclerosis disease in ESRD patients 331
(2) the leukocyte adhesion to the endothelium, and (3) de- prove to be predictive of cardiovascular mortality. Some
creases macrophage activity by releasing IL-1 Ra [25–27]. protective role is surely posited if we reflect that a reduc-
Transforming growth factor-1 has four actions to (1) tion by 1 ng/mL of TGF-1 is associated with a 9%
inhibit both migration and proliferation of smooth mus- increase in the risk of mortality.
cle cells and macrophages [15, 28]; (2) induce apoptosis The main result that emerges from our study is that
in numerous cells involved in the vascular lesions [29, 30]; our RDT patients had a significantly lower concentration
(3) reduce adhesiveness of the endothelium for inflam- of active TGF-1 than the control group of healthy sub-
matory cells [15, 31–33]; and (4) contribute to vascular jects. The low TGF-1 serum levels in our RDT patients
protection by inhibiting human metalloelastase identi- exclude the possibility that the two investigated genetic
fied in vulnerable areas of plaque and responsible for its patterns of production may ultimately affect TGF-1
instability [34]. serum levels. Indeed, the low-producer prevalence in
These experimental backgrounds have been confirmed our populations is only 5%.
by several clinical studies. In particular, Grainger et al The most significantly lowered levels occurred in pa-
found that serum levels of active TGF-1 were more se- tients with simultaneous evidence of coronary, cerebral
verely depressed in non-renal patients with advanced ath- and peripheral vascular disease. Among the patients with
erosclerosis than in persons without coronary atheroscle- ischemic heart disease, the lowest levels were found in
rosis [11]. McDonald et al found that increased serum those with significant stenoses of three major coronary
TGF-1 may exert a cardioprotective effect [35]. Subse- vessels. These results are in agreement with previous
quently Erren et al confirmed that TGF-1 serum levels reports regarding non-renal patients with so-called triple
are low in patients with severe ischemic heart disease [13]. vessel disease [11, 14].
In RDT patients, Suthanthiran et al found higher lev- Such a correlation between reduced TGF-1 levels and
els of serum TGF-1 in black than in white patients, and ischemic heart disease is related both to the antiprolifera-
suggested that this may be associated with the reduced tive effect of this cytokine on SMC and to its specific
incidence among the former of ischemic heart disease and cardioprotective effect. TGF-1 is able to counteract
death from myocardial infarction, and that this may ex- the release of TNF- into the blood after myocardial
plain the observation that blacks survive better than ischemia via a transcription and translation mechanism
whites on hemodialysis [36]. Grainger et al also found [45]. TGF-1 also reduces superoxide production in the
that (active  latent) TGF-1, and the proportions of ischemic coronary circulation by its endothelium pro-
TGF-1 that were active, were similar in serum and tecting effect, which it also achieves by suppressing leuko-
platelet poor plasma prepared from the same blood sam- cyte adhesion to endothelial cells even in the presence
ples [37]. Tashiro found significantly lower TGF-1
of inflammatory cytokines.plasma levels in patients with ischemic heart disease than
The cardiovascular protecting effect of TGF-1 is allin controls [14].
the more important considering that the cells targetedResearch into the role of TGF-1 in atherosclerotic
by TGF-1 come under the effect of other growth factorsand restenotic processes has given conflicting results.
such as PDGF-AB and MCSF, which interact with spe-Several articles indicate that TGF-1 tends to be highly
cific receptors promoting proliferative activity and thusexpressed at sites of vascular injury, particularly in hu-
counteract the effects of TGF-1. To further complicateman restenotic lesions [38, 39]. Conversely other authors
this broad scenario, our previous papers reported the sig-maintain that TGF-1 is a potent antiproliferative agent
nificant intradialytic platelet release of PDGF-AB thatfor vascular cells [40, 41] and that decreased activation
might predispose RDT patients to atherosclerosis [46, 47].of TGF-1 is associated with the progression of athero-
Unfortunately, the patients we studied had no ascer-sclerosis [11].
tained TGF-1 levels for the pre-dialytic period, so weThe differing pattern of expression of TGF-1 recep-
were unable to clarify if and how its concentration variedtors may hold a key to understanding the role of TGF-1
as hemodialysis treatment got underway.in the atherosclerotic process [30].
The absence of a TGF-1 inhibitory effect [42, 43] in
TGF- and traditional atherosclerotic risk factorsthe end leads to increased chemotaxis, increased extra-
Among the traditional atherosclerotic risk factors, agecellular matrix formation, cell proliferation and a decrease
seems to affect basal TGF-1 values only partially. Inin apoptosis. Thus, the resistance to apoptosis may lead
our study there was only a weak inverse correlation ofto the slow proliferation of cell subsets resistant to
TGF-1 levels with age occurring both for hemodialyisTGF-1, thereby contributing to the progression of ath-
patients (with or without cardiovascular diseases) anderosclerotic or restenotic lesions [30, 31, 44].
for the control group. There are no conclusive data in the
TGF- and cardiovascular disease literature on any correlation between age and TGF-1 in
non-renal patients [11]. This may be due to the shortageUsing a stepwise multiple regression analysis, only low
TGF-1 levels, apart from diabetes and serum albumin, of studies on the subject.
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No statistically significant difference in TGF-1 levels ratio 1.1). Again, among hemodialysis patients with car-
diovascular disease, albumin shows a significant, thoughemerges from our study between males and females
among our hemodialysis patients. By contrast in non- moderate, direct correlation with serum TGF-1 levels.
In our view, this result lends itself to at least to two inter-renal patients the TGF-1 serum level is thought to be
correlated with gender. Grainger in particular speculates pretations that need not be mutually exclusive: (1) both
parameters reflect the severity of vascular impairmentthat women’s TGF-1 levels may be under hormonal
regulation, especially considering the ascertained secretion and/or the degree of vascular inflammation; (2) as with
hypoalbuminemia, low TGF-1 values might express aof TGF-1 from fetal human fibroblasts by antiestrogens
[11]. Clearly, more extensive studies are needed to define state of malnutrition.
Among the acute phase proteins, Lp(a) is thought tothe role of gender and age on TGF-1 levels.
The incidence of diabetes mellitus in our population correlate in part with an inhibition of TGF-1 activation
[16, 53]. In accordance with previous reports our meanwas around 5%. Among the evaluated cardiovascular
risk factors, diabetes proved to have a higher role in values of Lp(a) prove higher in patients with known
cardiovascular disease than other RDT patients or theterms of mortality (odds ratio 3.38) in our study popula-
tion. However, no statistical difference emerged between control group [54–56]. Our results show a slight inverse
correlation between Lp(a) and TGF-1. This does notdiabetics and non-diabetics where TGF-1 levels were
concerned. seem sufficient in itself to account for the reduced basal
serum levels of TGF-1.It is well-known that high levels of LDL and reduced
levels of HDL are associated with an increased risk of It is possible, however, that the inflammatory process
inside the arterial wall enhances the pathophysiologicalcardiovascular mortality. Grainger finds an inverse cor-
relation between serum LDL cholesterol and the propor- effects of Lp(a), thus further reducing the activation
of TGF-1 [57]. In this connection we found a slighttion of active TGF-1, and proposes that the seques-
tration of TGF-1 to lipoprotein represents a possible correlation between Lp(a) and PCR.
Plasminogen activator inhibitor-1 is a 50 kD proteinmechanism for depression of TGF-1 activity in ad-
vanced atherosclerosis [48]. synthesized and released by endothelial cells. High PAI-1
levels have been shown to predict the risk of recurrentIf we look at our own patients, no correlation between
LDL and TGF-1 values was found; indeed, patients myocardial infarction in younger non-uremic men and
the occurrence of ischemic accidents in atheroscleroticwith the highest survival on dialysis show the highest
levels of LDL. Again, the multivariable regression model patients [58]. PAI-1 production can be stimulated by
oxidized LDL and cytokines such as TNF, both of whichdid not show any statistically significant correlation be-
tween total serum cholesterol or LDL concentration and are elevated in hemodialysis patients [17]. The pro-
atherogenic role of PAI-1 also is probably linked to itscardiovascular disease. As with total serum cholesterol,
we did not find any significant association between sys- property of blocking the activation of latent TGF-1 by
competitively inhibiting tPA. PAI-1 and Lp(a) promotetolic blood pressure and cardiovascular disease. The fact
that multivariable analysis showed no association be- SMC proliferation in culture by reducing the autocrine
inhibition caused by active TGF-1 [59, 60].tween the serum total cholesterol level or systolic blood
pressure and the presence of atherosclerotic cardiovas- In agreement with previous observations [61, 62], PAI-1
values in our hemodialysis patients proved higher thancular disease is at first sight somewhat surprising, but in
line with the results of other cohort studies [7, 8]. These among controls. The increase was more marked in car-
diovascular patients. These results could be related toobservations once again raise questions as to whether
the traditional cardiovascular risk factors are applicable the high plasma cytokine levels found in hemodialysis
patients and the degree of endothelium dysfunction. Into the chronic hemodialysis population.
our study PAI-1 levels showed a moderate inverse corre-
TGF-, albuminemia, and acute phase reaction lation with TGF-1 levels. These results seem to confirm
the experience of other authors with non-renal patients,The finding that hypoalbuminemia predicts death in
dialysis patients has been attributed to inflammation, that is to say, a moderately inhibiting effect by PAI-1
on TGF-1 exists. This effect might combine with themalnutrition and underdialysis [49]. Some authors have
recently found a link between both CRP and hypoalbum- similar inhibition by Lp(a) and partly explain the low
TGF-1 values.inemia and cardiovascular disease in both the general
population and in hemodialysis patients (abstract; Bergs-
TGF- and the hemodialysis proceduretro¨m et al, J Am Soc Nephrol 6:573, 1995) [50–52].
In our study the serum albumin levels are significantly Neither the type of membrane [cellulose modified
(HE) or synthetic (PAN, PS)] nor the technique usedlower in hemodialysis patients with cardiovascular disease,
and this correlates with CRP levels: albumin emerges as seemed to affect the basal serum TGF levels, there being
no significant differences among the membranes or thean independent risk factor for cardiovascular death (odds
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Table 8. aPTT intra- and post-dialytic values Conclusion
Time aPTT seconds Our study shows that TGF-1 serum levels are sig-
30 minutes 10724 nificantly reduced in hemodialysis patients, particularly
120 minutes 9022 in those with severe cardiovascular disease. The lower
240 minutes 7816
TGF-1 concentration may predispose the hemodialysis3 hours 438
patients to a worsening of atherosclerosis, in agreement
with what has been argued in non-renal patients. Hemo-
dialysis patients with severe cardiovascular disease showed
a negative moderate correlation of TGF-1 with raisedtechniques used. These findings would appear to dis-
levels of Lp(a) and PAI-1 and a moderate direct correla-count the possibility of TGF-1 basal values and the
tion with serum albumin levels. From the multivariableactivation pathway being somehow related to the biolog-
analysis it emerged that TGF-1 is an independent car-ical reaction directly caused by the blood-membrane con-
diovascular risk factor along with diabetes and hypo-tact, or this result being considered an expression of
albuminemia. Nonetheless, if we consider that reducedhigher or lower biocompatibility of the artificial materi-
TGF-1 levels also have been found in hemodialysisals. Our results are broadly in line with Suthanthiran’s
patients without cardiovascular disease, we can arguein vivo study that found no significant difference between
that the observed correlations are not the only possible“biocompatible” and “bioincompatible” membranes [36].
explanation of such a change in hemodialysis patients.On the other hand, they diverge from the Mege et al’s
Therefore, the low TGF-1 levels also could be hypo-in vitro experience [63].
thetically related to (1) subclinical endothelium damage,The intradialytic behavior of TGF-1 serum levels
or (2) heparin-mediated activation of TGF-1, whichshowed a marked reduction at 30 minutes (about 30%)
might lead to a reduction in TGF-1 serum values (ex-with a progressive return to basal values three hours
haustion) as a consequence of the subsequent link be-after the session’s end and without any difference related
tween TGF-1 and the TGF-1 receptor. Nevertheless,to the membrane and/or technique used. Though we
reduced TGF-1 levels still only can be considered ahave no proper explanation for this result, we do think
necessary, and not a sufficient, condition. The role ofthat removal across the dialyzer membrane may be ruled
TGF-1 in atherosclerosis needs further evaluation andout in view of the high molecular weight of this growth
correlation with other known risk factors by means offactor. However, the biology and the activation pathway
longer prospective controlled studies.of TGF-1 might well hold the key to interpreting the
result. In the circulation TGF-1 exists in two distinct,
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